{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Allarity Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ALLR"},"Address":{"label":"Address","value":"210 BROADWAY SUITE 201, CAMBRIDGE, Massachusetts, United States"},"Phone":{"label":"Phone","value":"+1 401 426-4664"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations."},"CompanyUrl":{"label":"Company Url","value":"https://www.allarity.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Marie L. Foegh","title":"Chief Medical Officer"},{"name":"Steen Meier Knudsen","title":"Chief Scientific Officer"},{"name":"Thomas H. Jensen","title":"Director &amp; SVP-Information Technology"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}